MK-7262

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Elevated lipoprotein(a)HealthyLipoprotein(a)

Phase 1

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Active, not recruitingNCT07619443

Merck Sharp & Dohme LLCHealthy

Start: 2026-07-01End: 2026-09-12Target: 30Updated: 2026-08-05

Phase 2

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

RecruitingNCT07614984

Merck Sharp & Dohme LLCLipoprotein(a)

Start: 2026-06-30End: 2027-10-12Target: 750Updated: 2026-09-09

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Not yet recruitingCTIS2025-525102-38-00

Merck Sharp & Dohme LLCElevated lipoprotein(a)

Target: 125Updated: 2026-08-18